Press release
Parkinson's Disease Market to Reach USD 11.92 Billion by 2030
Parkinson's Disease Market
Introduction
The Parkinson's Disease (PD) Market is entering a transformative phase as pharmaceutical companies accelerate the development of disease-modifying therapies, advanced dopamine agonists, L-dopa reformulations, gene-based treatments, cell-replacement therapies, and digital monitoring solutions.
With more than 10 million patients worldwide, Parkinson's continues to be one of the fastest-growing neurodegenerative disorders. Increasing diagnosis, aging populations, and innovation in neurotherapeutics are significantly fueling market growth across the U.S., Europe, and Asia-Pacific.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/73645
Key Takeaways
• Market Size (2023): USD 7.85 Billion
• Expected Market Size (2030): USD 11.92 Billion
• CAGR (2024-2030): 6.1%
• Growth driven by long-acting formulations, combination therapy, and next-generation neuroprotective drugs.
• Key companies include AbbVie, Novartis, GlaxoSmithKline (GSK), Teva, Amneal, UCB, Acorda Therapeutics, Neurocrine Biosciences, Biogen, Merck, and Acadia Pharmaceuticals.
• Strong pipeline interest in gene therapy (AAV-based), stem cell therapy, LRRK2 inhibitors, α-synuclein antibodies, and precision neuromodulation devices.
Market Story
Parkinson's disease drug development is undergoing a major shift from symptomatic treatments to disease-modifying and regenerative strategies.
1. Rise of Long-Acting & Continuous Dopamine Delivery
Innovations include:
• Extended-release levodopa formulations
• Continuous subcutaneous infusion systems
• Long-acting patches and inhalation formulations
These reduce "off episodes" and improve motor function stability.
2. Advances in Disease-Modifying Therapies (DMTs)
New therapy classes are progressing through clinical trials:
• LRRK2 kinase inhibitors
• α-synuclein immunotherapies
• Mitochondrial protective drugs
• Nrf2 pathway activators
These target underlying neurodegeneration mechanisms.
3. Cell & Gene Therapy Momentum
Breakthroughs include:
• AAV-based gene therapies to boost dopamine production
• CRISPR-enabled neuroregeneration
• Stem-cell derived dopaminergic neuron transplantation
• Autologous cell therapies for personalized treatment
4. Digital Diagnostics & Remote Monitoring
AI-driven and wearable monitoring tools (tremor sensors, gait analysis, remote symptom scoring) support better disease management.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/73645/parkinson-s-disease-market
Market Segments
By Drug Class
• Levodopa & Carbidopa Combinations (largest segment)
• Dopamine Agonists
• MAO-B Inhibitors
• COMT Inhibitors
• Anticholinergic Agents
• Adenosine A2A Antagonists
• Glutamate Modulators
• Emerging Neuroprotective Agents
By Route of Administration
• Oral
• Injectable
• Transdermal
• Inhalation
• Implantable/Continuous Infusion Systems
By Patient Type
• Early-Stage PD
• Mid-Stage PD
• Advanced/Refractory PD
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Clinics
• Online Pharmacies
Recent Developments
• AbbVie expanded global access to Duopa/Duodopa pump therapy for advanced PD.
• Amneal launched IPX203 extended-release carbidopa/levodopa, improving "on-time" duration.
• UCB advanced its α-synuclein antibody into mid-stage trials.
• Biogen strengthened its neurodegeneration pipeline through strategic acquisitions.
• Neurocrine Biosciences reported promising results for its novel VMAT2 inhibitor in PD dyskinesia.
• GSK and Novartis invested heavily in new neuroprotective drug strategies.
Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=73645
Expert Quote
"Parkinson's disease treatment is shifting from symptom control toward true disease modification. Emerging gene therapies, long-acting formulations, and regenerative approaches are reshaping the future treatment landscape."
-Irfan Tamboli, Business Development Executive, Exactitude Consultancy
Market Drivers
• Rising global prevalence & aging populations
• Increased early diagnosis & awareness programs
• Growth of neuroprotective drug pipelines
• Strong investment in gene therapy & stem-cell research
• Advanced drug-delivery systems reducing motor fluctuations
• Digital neurology & wearable-based disease monitoring
Forecast Outlook
The global market will reach USD 11.92 billion by 2030, driven by:
• Launch of novel DMTs (disease-modifying therapies)
• Expansion of infusion pumps, patches & inhalation therapies
• Increased adoption of tele-neurology platforms
• Growth in Japan & EU neurodegenerative therapy spending
Regional Highlights
• North America leads due to strong biologics pipeline and high treatment uptake.
• Europe grows steadily due to structured reimbursement & specialty neurology centers.
• Asia-Pacific is the fastest-growing region, driven by aging populations and improving diagnosis rates.
Government & Regulatory Initiatives
• FDA breakthrough designations for neuroprotective therapies
• NIH & EU funding for Parkinson's precision medicine programs
• Japan PMDA support for regenerative therapy pathways
• National aging & neurodegenerative disease policies boosting access
• Digital therapeutics approvals accelerating remote patient monitoring
Conclusion
The Parkinson's Disease Market is evolving rapidly, with strong momentum in biologics, gene therapy, and long-acting therapeutic platforms. Companies investing in disease-modifying therapeutics, precision neurology, and advanced delivery systems will define the next decade of neurodegenerative care.
This report is also available in the following languages : Japanese (パーキンソン病市場), Korean (파킨슨병 시장), Chinese (帕金森病市场), French (Marché de la maladie de Parkinson), German (Parkinson-Krankheitsmarkt), and Italian (Mercato del morbo di Parkinson), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/73645
Our More Reports:
Biologics Fill Finish Manufacturing Market
https://exactitudeconsultancy.com/reports/73133/biologics-fill-finish-manufacturing-market
Clinical Trial Services Market
https://exactitudeconsultancy.com/reports/73135/clinical-trial-services-market
Biologics Contract Manufacturing Market
https://exactitudeconsultancy.com/reports/73137/biologics-contract-manufacturing-market
Clinical Trial Patient Recruitment Services Market
https://exactitudeconsultancy.com/reports/73139/clinical-trial-patient-recruitment-services-market
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Disease Market to Reach USD 11.92 Billion by 2030 here
News-ID: 4302008 • Views: …
More Releases from Exactitude Consultancy
Natural Killer (NK) Cell Therapies Market with CAGR 19.3% 2025-2034
The Global Natural Killer (NK) Cell Therapies Market is rapidly evolving due to rising clinical success of NK cell-based immunotherapies, strong investment in oncology drug development, and high demand for effective treatments against hematologic and solid tumors. NK cell therapies offer significant advantages-including innate tumor-killing ability, lower risk of graft-versus-host disease, and enhanced safety profiles compared to CAR-T therapies.
Market Size & Growth Outlook
• Market Value (2024): USD 2.1 Billion
• Forecast Value (2034):…
Vaccine Contract Manufacturing Market Trades ,Demands 2034
The Global Vaccine Contract Manufacturing Market is experiencing strong momentum as pharmaceutical and biotechnology companies increasingly outsource vaccine production, fill-finish operations, and large-scale formulation to specialized CDMOs. The need for faster commercialization, cost optimization, and advanced biologics manufacturing capabilities-especially after the COVID-19 era-has accelerated the demand for high-quality contract manufacturing services worldwide.
Market Size & Growth Outlook
• Market Value (2024): USD 4.8 Billion
• Forecast Value (2034): USD 12.9 Billion
• CAGR (2025-2034): 10.4%
The market will…
Mitochondrial Disease Therapies Market Demand 2034
Market Overview
The Mitochondrial Disease Therapies Market is experiencing strong growth as awareness, diagnosis rates, and clinical research activity surrounding rare mitochondrial disorders increase worldwide. Mitochondrial diseases, often caused by inherited or spontaneous mutations affecting cellular energy production, currently have limited approved treatments, driving significant unmet medical need and investment in novel therapeutics.
The market is projected to expand steadily through 2024-2034, supported by gene therapy advancements, targeted drug development, and improved…
Antibody-Drug Conjugate (ADC) Market to Surpass USD 30 Billion by 2034 as Oncolo …
The Antibody-Drug Conjugate (ADC) Market is experiencing explosive growth as ADCs become one of the fastest-expanding segments in oncology therapeutics. With more than a dozen commercialized ADC drugs and hundreds of candidates in development, pharmaceutical companies are investing aggressively in targeted cancer therapies that deliver high efficacy with reduced systemic toxicity.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/73125
What Are Antibody-Drug Conjugates (ADCs)?
ADCs are targeted cancer therapies that combine:
• A monoclonal…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.43 billion…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
